{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:24:49Z","timestamp":1784942689723,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006432","name":"Terumo BCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.transci.2024.103988","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T16:53:17Z","timestamp":1723135997000},"page":"103988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Position paper on advancing sickle cell disease management in France by bridging the clinical practices and guidelines through expert insights"],"prefix":"10.1016","volume":"63","author":[{"given":"K.","family":"Benmoussa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bernaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Connes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"H\u00e9quet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2024.103988_bib1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/hematology.2021000307","article-title":"Indications for transfusion in the management of sickle cell disease","volume":"2021","author":"Han","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.transci.2024.103988_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253986","article-title":"Epidemiology and disease burden of sickle cell disease in France: a descriptive study based on a French nationwide claim database","volume":"16","author":"Leleu","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.transci.2024.103988_bib3","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282098","article-title":"Severity and burden of sickle cell disease in France: a nationwide realworld study","author":"Brousse","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2024.103988_bib4","unstructured":"Inc G.B.T. New G.B.T. Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease. GlobeNewswire News Room 2022. \u3008https:\/\/www.globenewswire.com\/news-release\/2022\/06\/13\/2461183\/37049\/en\/New-GBT-Multinational-Survey-Shines-a-Needed-Light-on-the-Misunderstood-Realities-Unseen-Burden-and-Care-Challenges-of-Sickle-Cell-Disease.html\u3009 (accessed August 17, 2023)."},{"key":"10.1016\/j.transci.2024.103988_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s13023-021-02096-6","article-title":"A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease","volume":"16","author":"Zaidi","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.transci.2024.103988_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0268-960X(02)00074-7","article-title":"The role of hydroxyurea in the management of sickle cell disease","volume":"17","author":"Davies","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.transci.2024.103988_bib7","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2024.103988_bib8","first-page":"500","article-title":"Epidemiology of sickle cell disease in France and in the world","volume":"73","author":"Arlet","year":"2023","journal-title":"Rev Prat"},{"key":"10.1016\/j.transci.2024.103988_bib9","unstructured":"Revue de Biologie M\u00e9dicale. (2019). Dr\u00e9panocytose et transfusion. [PDF file]. Retrieved from \u3008https:\/\/www.revuebiologiemedicale.fr\/images\/Infos_bio\/317_DREPANOCYTOSE_TRANSFUSION_BEH.pdf\u3009."},{"key":"10.1016\/j.transci.2024.103988_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the Writing Committee of the American Society for Apheresis: the Ninth Special Issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2024.103988_bib11","unstructured":"Overview | Spectra Optia for automatic red blood cell exchange in people with sickle cell disease | Guidance | NICE 2016. \u3008https:\/\/www.nice.org.uk\/guidance\/mtg28\u3009 (accessed October 10, 2023)."},{"key":"10.1016\/j.transci.2024.103988_bib12","unstructured":"Transfusions de globules rouges homologues\u00a0: produits, indications, alternatives. Haute Aut Sant\u00e9 n.d. \u3008https:\/\/www.has-sante.fr\/jcms\/c_1349939\/fr\/transfusions-de-globules-rouges-homologues-produits-indications-alternatives\u3009 (accessed October 10, 2023)."},{"key":"10.1016\/j.transci.2024.103988_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2014.1.450","article-title":"Red cell exchange: special focus on sickle cell disease","volume":"2014","author":"Kim","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.transci.2024.103988_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/asheducation-2013.1.439","article-title":"Transfusion therapy for sickle cell disease: a balancing act","volume":"2013","author":"Chou","year":"2013","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.transci.2024.103988_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jpeds.2006.06.037","article-title":"Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia","volume":"149","author":"Hulbert","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.transci.2024.103988_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.transci.2017.05.020","article-title":"A 5-year cost analysis of automated red cell exchange transfusion for the management of recurrent painful crises in adult patients with sickle cell disease","volume":"56","author":"Tsitsikas","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.transci.2024.103988_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.tmrv.2004.03.002","article-title":"Leukoreduction filtration of blood with sickle cell trait","volume":"18","author":"Schuetz","year":"2004","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2024.103988_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000762","article-title":"Precision medicine and sickle cell disease","volume":"6","author":"El Hoss","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.transci.2024.103988_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/trf.14495","article-title":"Vascular access for red blood cell exchange","volume":"58","author":"Otrock","year":"2018","journal-title":"Transfus (Paris)"},{"key":"10.1016\/j.transci.2024.103988_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.transci.2019.03.004","article-title":"Recommendations for the use of red blood cell exchange in sickle cell disease","volume":"58","author":"Fort","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2024.103988_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1526-0968.2002.00396.x","article-title":"The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease","volume":"6","author":"Danielson","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.transci.2024.103988_bib22","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood.V120.21.2281.2281","article-title":"A comparison of automated red blood cell depletion\/exchange to automated red cell blood exchange in sickle cell patients","volume":"120","author":"Kuo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.103988_bib23","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1111\/trf.15188","article-title":"Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients","volume":"59","author":"Hequet","year":"2019","journal-title":"Transfus (Paris)"},{"issue":"5","key":"10.1016\/j.transci.2024.103988_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jca.21511","article-title":"Red blood cell exchange: 2015 American Society for Apheresis consensus conference on the management of patients with sickle cell disease","volume":"32","author":"Sarode","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2024.103988_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-022-01237-z","article-title":"Advances in the diagnosis and treatment of sickle cell disease","volume":"15","author":"Brandow","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.transci.2024.103988_bib26","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.103988_bib27","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2018-02-785964","article-title":"How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions","volume":"131","author":"Pirenne","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2024.103988_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/trf.14407","article-title":"Case series supporting heme detoxification via therapeutic plasma exchange in acute multiorgan failure syndrome resistant to red blood cell exchange in sickle cell disease","volume":"58","author":"Louie","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2024.103988_bib29","doi-asserted-by":"crossref","first-page":"E629","DOI":"10.1002\/ajh.24870","article-title":"Plasmapheresis may improve clinical condition in sickle cell disease through its effects on red blood cell rheology","volume":"92","author":"Nader","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2024.103988_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2022.103375","article-title":"Therapeutic plasma exchange in the management of acute complications of sickle cell disease: a single centre experience","volume":"61","author":"Tsitsikas","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2024.103988_bib31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/trf.17448","article-title":"Plasma exchange\u2014a useful adjunct therapy to red cell exchange in patients with sickle cell disease and multiorgan dysfunction","volume":"63","author":"Webb","year":"2023","journal-title":"Transfus (Paris)"},{"key":"10.1016\/j.transci.2024.103988_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.transci.2006.12.009","article-title":"Plasma exchange in critically ill patients with sickle cell disease","volume":"37","author":"Boga","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2024.103988_bib33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjh.18059","article-title":"Expanded eligibility for emerging therapies in sickle cell disease in the UK \u2013 crizanlizumab and voxelotor","volume":"197","author":"Vora","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2024.103988_bib34","unstructured":"British Journal of Haematology | Wiley Online Library n.d. \u3008https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/bjh.16504?sid=nlm%3Apubmed\u3009 (accessed November 28, 2023)."},{"key":"10.1016\/j.transci.2024.103988_bib35","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","article-title":"Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Howard","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.transci.2024.103988_bib36","unstructured":"E.M.A. Adakveo. Eur Med Agency 2023. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/adakveo\u3009 (accessed October 10, 2023)."},{"key":"10.1016\/j.transci.2024.103988_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-136308","article-title":"Outcomes of chronic automated RBC exchange program in Omaha, Nebraska 2015-2020","volume":"136","author":"Bobr","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.103988_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/ajts.ajts_13_21","article-title":"Comparative study between chronic automated red blood cell exchange and manual exchange transfusion in patients with sickle cell disease: a single center experience from Saudi Arabia","volume":"17","author":"Al Mozain","year":"2023","journal-title":"Asian J Transfus Sci"},{"key":"10.1016\/j.transci.2024.103988_bib39","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood.V120.21.2281.2281","article-title":"A comparison of automated red blood cell depletion\/exchange to automated red cell blood exchange in sickle cell patients","volume":"120","author":"Kuo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.transci.2024.103988_bib40","unstructured":"Dedeken L., L\u00ea P.Q., Rozen L., El Kenz H., Huybrechts S., Devalck C., et al. Automated RBC exchange compared to manual exchange transfusion for children with sickle cell disease is cost-effective and reduces iron overload. Transfusion (Paris)."},{"key":"10.1016\/j.transci.2024.103988_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the Eighth Special Issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T20:01:38Z","timestamp":1725998498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050224001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1473050224001599"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.103988","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Position paper on advancing sickle cell disease management in France by bridging the clinical practices and guidelines through expert insights","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.103988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103988"}}